Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001909524 | SCV002182586 | uncertain significance | not provided | 2023-07-25 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1408485). This variant has not been reported in the literature in individuals affected with CCT2-related conditions. This variant is present in population databases (rs377377290, gnomAD 0.01%). This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 176 of the CCT2 protein (p.Lys176Gln). |
Ambry Genetics | RCV004042790 | SCV003873646 | uncertain significance | not specified | 2023-02-28 | criteria provided, single submitter | clinical testing | The c.526A>C (p.K176Q) alteration is located in exon 7 (coding exon 7) of the CCT2 gene. This alteration results from a A to C substitution at nucleotide position 526, causing the lysine (K) at amino acid position 176 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |